Latest Regulatory Development News

nib holdings limited signals higher-than-expected non-recurring expenses in the first half of 2026, impacting statutory profit but leaving underlying performance steady.

Bendigo and Adelaide Bank has been hit with a $50 million operational risk capital charge by APRA, while AUSTRAC launches an enforcement investigation into serious AML/CTF breaches. The bank commits to intensifying risk management efforts amid regulatory scrutiny.

Whitebark Energy’s latest technical review of the Warro Gas Field reveals that water production issues are confined to specific fault zones, enhancing prospects for commercial gas flow and prompting immediate engineering evaluations.

ECS Botanics is strategically preparing for entry into the US medicinal cannabis market, leveraging its EU-GMP certification and proprietary genetics amid evolving regulatory landscapes.

4DMedical has locked in $30.2 million through an underwriting agreement ensuring full exercise of its listed options, lifting its cash reserves to $63.7 million and setting the stage for a pivotal year in commercialising its CT – VQ™ technology.

DigiCo Infrastructure REIT appoints Michael Juniper as CEO, signaling a strategic push into advanced data centre development amid rising cloud and AI demand. Chris Maher shifts focus to government relations, underscoring regulatory challenges ahead.

Island Pharmaceuticals has secured over $1 million through option exercises by directors and major shareholders, bolstering its cash reserves to advance the clinical and regulatory development of its broad-spectrum antiviral, Galidesivir.

Viridis Mining and Minerals advances its Colossus Rare Earth Project with a favorable environmental assessment, despite a temporary regulatory pause to address public prosecutor concerns.

Big River Industries Ltd (ASX, BRI) is set to acquire John’s Building Supplies, a leading Western Australian distributor, in a $17 million deal that promises immediate earnings accretion and strategic growth in the WA market.

Southern Cross Media Group has secured crucial ACMA approval for its proposed merger with Seven West Media, advancing a major consolidation in Australia’s media landscape. The deal now moves closer to final shareholder approval.

Aroa Biosurgery has reported a strong first half for FY26, with 14% revenue growth driven by its Myriad product line and a return to positive EBITDA. The company also secured relief from ASX quarterly reporting requirements, signaling improved financial stability.

Aroa Biosurgery reported a 14% rise in product sales to NZ$44.6 million for the half-year ended September 2025, driven by strong growth in its Myriad portfolio. The company also posted a normalised EBITDA profit and reaffirmed its FY26 revenue and profit guidance.